Inogen, Inc $INGN Shares Sold by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC reduced its holdings in Inogen, Inc (NASDAQ:INGN) by 10.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,244 shares of the medical technology company’s stock after selling 7,359 shares during the quarter. Campbell & CO Investment Adviser LLC owned approximately 0.23% of Inogen worth $431,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC grew its holdings in Inogen by 11.0% in the 2nd quarter. CWM LLC now owns 16,258 shares of the medical technology company’s stock valued at $114,000 after buying an additional 1,611 shares during the period. Cubist Systematic Strategies LLC boosted its position in shares of Inogen by 1.4% in the first quarter. Cubist Systematic Strategies LLC now owns 124,993 shares of the medical technology company’s stock worth $891,000 after acquiring an additional 1,751 shares during the last quarter. American Century Companies Inc. grew its holdings in Inogen by 6.4% in the first quarter. American Century Companies Inc. now owns 58,380 shares of the medical technology company’s stock valued at $416,000 after purchasing an additional 3,524 shares during the period. Deutsche Bank AG increased its position in Inogen by 61.6% during the first quarter. Deutsche Bank AG now owns 14,856 shares of the medical technology company’s stock worth $106,000 after purchasing an additional 5,664 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in Inogen by 44.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 20,078 shares of the medical technology company’s stock worth $150,000 after purchasing an additional 6,220 shares during the last quarter. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Stock Up 0.3%

Inogen stock opened at $6.90 on Monday. The firm has a fifty day moving average of $8.23 and a 200-day moving average of $7.35. Inogen, Inc has a 52-week low of $5.70 and a 52-week high of $12.91. The firm has a market capitalization of $187.34 million, a P/E ratio of -6.83 and a beta of 1.83.

Inogen (NASDAQ:INGN) last posted its earnings results on Wednesday, November 5th. The medical technology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. Inogen had a negative net margin of 7.31% and a negative return on equity of 13.21%. The business had revenue of $92.39 million for the quarter, compared to analyst estimates of $92.20 million. Inogen has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that Inogen, Inc will post -1.73 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Inogen has an average rating of “Hold” and a consensus target price of $11.00.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.